Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses

dc.contributor.authorAlemany, R.en
dc.contributor.authorGomez-Manzano, C.en
dc.contributor.authorBalague, C.en
dc.contributor.authorYung, W. K.en
dc.contributor.authorCuriel, D. T.en
dc.contributor.authorKyritsis, A. P.en
dc.contributor.authorFueyo, J.en
dc.date.accessioned2015-11-24T19:15:02Z
dc.date.available2015-11-24T19:15:02Z
dc.identifier.issn0014-4827-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21438
dc.rightsDefault Licence-
dc.subjectAdenoviruses, Human/genetics/physiologyen
dc.subjectBrain Neoplasms/genetics/*therapyen
dc.subjectClinical Trials as Topicen
dc.subjectGene Therapy/*methodsen
dc.subjectGenes, Tumor Suppressoren
dc.subjectGenetic Vectorsen
dc.subjectGlioblastoma/genetics/therapyen
dc.subjectGlioma/genetics/*therapyen
dc.subjectHelper Viruses/geneticsen
dc.subjectHumansen
dc.subjectSyndromeen
dc.subjectTumor Markers, Biological/geneticsen
dc.subjectVirus Replicationen
dc.titleGene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenovirusesen
heal.abstractCurrently, most of the approved clinical gene therapy protocols involve cancer patients and several of the therapies are designed to treat brain tumors. Two factors promoting the use of gene therapy for gliomas are the failure and toxicity of conventional therapies and the identification of the genetic abnormalities that contribute to the malignancy of gliomas. During the malignant progression of astrocitic tumors several tumor suppressor genes are inactivated, and numerous growth factors and oncogenes are overexpressed progressively. Thus, theoretically, brain tumors could be treated by targeting their fundamental molecular defects, provided the gene-drug can be delivered to a sufficient number of malignant cells. However, gene therapy strategies have not been abundantly successful clinically, in part because the delivery systems are still imperfect. In the first part of this brief review we will discuss the most common targets for gene therapy in brain tumors. In the second part, we will review the evolution of adenoviruses as gene vehicles. In addition, we will examine the role of recombinant mutant oncolytic adenoviruses as anticancer tools. From the results to date it is clear that gene therapy strategies for brain tumors are quite promising but more critical research is required, mainly in the vector field, if the strategies are to achieve their true potential in ameliorating patients with gliomas.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1006/excr.1999.4623-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10502394-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0014482799946232/1-s2.0-S0014482799946232-main.pdf?_tid=9b6ded23b781366f0b1ded669e8d4f3c&acdnat=1332860176_06ab2bdac6b3e84424e712313bded88c-
heal.journalNameExp Cell Resen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1999-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Φόρτωση...
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή: